Dr. Andrew Steele

A Community Nephrologist at Lakeridge Health for 20 years after coming from St. Michael’s Hospital in Toronto where he was a Clinical Investigator in the Division of Nephrology.

After 14 years, he has recently stepped down as Medical Director and Section Chief of Nephrology and Diabetes at Lakeridge. Dr. Steele served as the Executive and Regional Lead Nephrologist for the Ontario Renal Network 7 years.

Dr. Steele received training at the University of Toronto in the fields of Internal Medicine, Nephrology and Clinical Epidemiology. He is a former member of the Canadian Diabetes Association Clinical Guidelines Committee and has research and clinical interests in Diabetes, CKD, Dialysis and Vascular Disease in the CKD population. He is still active in guideline development and dissemination of knowledge.

Dr. Steele is very active in a busy clinical Nephrology practice at Lakeridge Health with a strong interest in Clinical research serving currently as a Principal Investigator on 17 ongoing trials in the fields of CKD, Diabetes, and vascular disease, including the recently started SAFE-HD trial of Apixaban vs Warfarin and Placebo in Dialysis Patients with Atrial Fibrillation. Other recent and ongoing |trials of interest include - CANVAS, CREDENCE, DAPA-CKD, EMPA-Kidney, FIDELIO, FIGARO, FLOW and SCORED.

 

EDUCATION
• University of Toronto
• Internal Medicine
• Nephrology
• Clinical Epidemiology

CLINICAL AND RESEARCH INTERESTS
• Diabetes
• CKD Progression
• Diabetic Kidney Disease
• Vascular Risk in CKD
• Hypertension
• Atrial Fibrillation and Stroke Prevention

Email: asteele@lh.ca